A Clinical Study of KLH-2109 in Patients With Endometriosis
Kissei Pharmaceutical Co., Ltd. · Endometriosis
Phase 3
Active, not recruiting
288
2026-03
Industry sponsor intelligence
Kissei Pharmaceutical Co., Ltd.Clinical Pipeline.
Lead-sponsor view of Kissei Pharmaceutical Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 1
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 288
Pipeline overview
Programs by phase and activity.
Velocity
Kissei Pharmaceutical Co., Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Leuprolide → | 1 | 0 | 0 | 1 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Kissei Pharmaceutical Co., Ltd. studies.
This page groups studies where Kissei Pharmaceutical Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates